Common name: CB17 SCID
JAX stock no. 001803
Commonly referred to as CB17 SCID or BALB/c SCID, these animals carry the severe combined immune deficiency mutation (scid) on the BALB/c background. This strain does not carry the C5 complement deficient mutation, thus enabling Complement-Dependent Cytotoxicity (CDC), a major pharmacological effect of therapeutic antibodies. This is the strain of choice for efficacy testing of therapeutic antibodies in the context of transplantable tumor host.
Characteristics: Mice homozygous for the severe combined immune deficiency spontaneous mutation (Prkdc scid, commonly referred to as scid) are characterized by an absence of functional T cells and B cells, lymphopenia, hypogammaglobulinemia, and a normal hematopoietic microenvironment. Normal antigen-presenting cell, myeloid, and NK cell functions are strain dependent. Scid mice carry a DNA repair defect and a defect in the rearrangement of genes that code for antigen-specific receptors on lymphocytes.
Disease/therapeutics areas used:
- Cancer research
- B and T cell deficiency, xenograft/transplant host
- Immunology, Inflammation and Autoimmunity Research
- B and T cell deficiency
- Internal/Organ Research
- Lymphoid Tissue Defects
- Virology Research
- B and T Cell Deficiency- AIDS research tool
To get further details on availability and to place your orders, please contact our Marketing or Customer Service Team at firstname.lastname@example.org.